Matinas BioPharma Holdings, Inc.

Matinas BioPharma is a clinical-stage biopharmaceutical company developing drug delivery solutions using its proprietary lipid nanocrystal (LNC) platform technology. The LNC platform is designed to enhance the delivery of various therapeutic modalities, including small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. This delivery approach addresses formulation challenges that have historically limited the therapeutic potential of certain drug candidates.

The company's lead product candidate, MAT2203, is an oral formulation of amphotericin B currently entering Phase 3 clinical trials for treating aspergillosis and cryptococcosis, as well as preventing invasive fungal infections in immunosuppressed patients. Amphotericin B has been a standard antifungal therapy but requires intravenous administration due to poor oral bioavailability; the oral formulation seeks to improve patient convenience and tolerability. The company also has MAT2501, an oral amikacin formulation, in development. Matinas maintains strategic partnerships with the National Institute of Allergy and Infectious Diseases, BioNTech to evaluate mRNA-LNC combinations, and Genentech for oral formulation development.

Based in Bedminster, New Jersey, the company operates with a minimal workforce of three full-time employees. As a pre-revenue clinical-stage company, Matinas is dependent on partnerships, grants, and capital raises to fund its development activities and operations.